Related references
Note: Only part of the references are listed.
Article
Medicine, General & Internal
Lecanemab in Early Alzheimer's Disease
Christopher H. van Dyck et al.
Summary: Lecanemab, a humanized monoclonal antibody, reduced amyloid markers and showed improvement in cognition and function in early Alzheimer's disease patients. However, it also resulted in adverse events. Longer trials are needed to determine its efficacy and safety in early Alzheimer's disease.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
Share Paper
